Biopsomic

Biopsomic and HEPIA Tissue Engineering laboratory of Prof Adrien Roux have initiated a scientific collaboration in 2022 to expand the potential of liquid biopsy in cancer patients. This innovative approach is based on the characterization of nanometer-sized extracellular vesicles (EVs) circulating in the patient blood, which can be collected from a simple blood draw. These EVs, called exosomes, are carriers of biochemical clues such as cancer biomarkers that reflect the disease process. Biopsomic assists oncologists in evaluating cancer patients’ prognostics and in electing appropriate treatment and management strategies from this biochemical information.

The Tissue Engineering Laboratory is providing its expertise to optimize the exosomes purification and characterization from blood plasma with a range of technologies such as size exclusion chromatography, immunoassay (ELISA), Transmission Electron Microscopy (TEM) and Dynamic Light Scattering (DLS) (with the contribution of HEPIA’s Materials and Tribology Group of Assistant Professor Irena Milosevic). These new insights will allow oncologists to make well-informed clinical decisions and ensure optimal patient outcomes.

About Biopsomic:
Dr Antoine Leimgruber and João-Antonio Brinca co-founded the start-up Biopsomic in 2019. This company is based on a patented liquid biopsy solution for cancer prognosis resulting from a collaborative research with Prof Andreas Möller (Queensland Institute of Medical Research, Australia). This approach involves the analysis of nanometric vesicles secreted by cancer cells and circulating in the patient blood. With this approach, Biopsomic has identified the biochemical signature of aggressive cancers that can cause metastasis.